α-Gal A Mutation Response Profiling for DGJ Chaperone Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lysosomal storage disorders, such as Fabry disease, are ineffective due to the inability to predict patient responsiveness to substrate reduction therapy (SRT) without invasive screening methods, and existing enzyme replacement therapies face challenges like rapid protein degradation and low bioavailability.
Innovation Solution
An in vitro assay using 1-deoxygalactonojirimycin (DGJ) to determine if a mutant protein's activity can be enhanced, allowing for personalized SPC therapy tailored to specific mutations, and a treatment reference table to guide therapeutic approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological chaperone therapy is used to treat lysosomal storage disorders, then enzyme activity and clinical outcomes may be improved, but the inability to predict patient responsiveness leads to inefficient and costly treatment approaches
Solution Approach 1:
The patent applies preliminary action by developing and implementing an in vitro assay that predicts patient responsiveness to pharmacological chaperone therapy before treatment begins. The assay uses patient-derived cells to evaluate enzyme activity in the presence of candidate chaperones, allowing clinicians to identify responsive patients in advance and avoid ineffective treatments, thereby resolving the contradiction between improving treatment efficacy and reducing treatment selection time
Solution Approach 2:
The patent applies feedback by creating a predictive assay that provides information about patient responsiveness to pharmacological chaperone therapy. The assay results feed back into treatment decision-making, allowing clinicians to select appropriate patients for therapy based on predicted responsiveness rather than attempting treatment empirically, thus improving reliability while reducing time loss
2Reliability
If pharmacological chaperone therapy is attempted without predictive testing, then treatment costs are reduced, but treatment efficacy decreases due to inability to identify responsive patients
Solution Approach 1:
The patent applies copying by using patient-derived cells (such as fibroblasts or lymphocytes) as a surrogate system to predict in vivo treatment responsiveness. The in vitro assay creates a simplified copy of the patient's enzymatic system that can be tested with candidate chaperones, providing predictive information without requiring complex in vivo trials, thus improving treatment efficacy while managing testing complexity
Solution Approach 2:
The patent applies the principle of using disposable, easily obtainable patient-derived cells for testing. These cells can be obtained through routine blood draws or skin biopsies and used for in vitro assessment of chaperone responsiveness. The cells serve as a single-use testing medium that provides predictive information without requiring long-term cell culture or complex maintenance, balancing treatment efficacy with manageable complexity
3Adaptability or versatility
If standard enzyme replacement therapy is used for all patients, then treatment simplicity is maintained, but treatment effectiveness varies due to mutant enzyme variability
Solution Approach 1:
The patent applies local quality by tailoring treatment to individual patients based on their specific mutant enzyme characteristics and responsiveness to pharmacological chaperones. The in vitro assay evaluates each patient's unique enzymatic profile and predicts which patients will respond to chaperone therapy versus those who would benefit from standard enzyme replacement therapy, enabling personalized treatment selection that adapts to local patient-specific conditions rather than applying a uniform approach
Solution Approach 2:
The patent applies parameter changes by using the in vitro assay to identify variations in enzyme responsiveness to pharmacological chaperones among different patients and mutant types. The assay measures changes in enzyme activity parameters in the presence of candidate chaperones, allowing clinicians to select patients whose enzymatic parameters indicate responsiveness to alternative therapy, thus achieving treatment personalization while managing decision complexity through objective measurements
Data Source
Figure 1A
Figure 1B
Figure 1B
AI summary
A method of compiling a treatment reference table that indicates the responsiveness of one or more specific mutations of α-Gal A to a specific pharmacological chaperone, the method comprising: analysing in vitro the response to the specific pharmacological chaperone in a host cell that has been transformed with a nucleic acid vector that encodes a first mutant α-Gal A and compiling a table listing responsive and non-responsive mutant forms of α-Gal A. The specific pharmacological chaperone is 1-deoxygalactonojirimycin or a pharmaceutically salt or ester and the first cell is HEK-293 MSR cell.